Inhibition of the mevalonate pathway improves myocardial fibrosis DOI Open Access

Huifeng Xu,

Yi Shen, Chenyu Liang

et al.

Experimental and Therapeutic Medicine, Journal Year: 2021, Volume and Issue: 21(3)

Published: Jan. 18, 2021

The mevalonate (MVA) pathway serves an important role in ventricular remodeling. Targeting the MVA has protective effects against myocardial fibrosis. present study aimed to investigate mechanism behind these effects. Primary cultured cardiac fibroblasts from C57BL/6 mice were treated in vitro 5 groups: i) negative control; ii) angiotensin II (Ang II) model (1x10‑5 mol/l); iii) Ang + rosuvastatin (ROS); iv) alendronate (ALE); and v) fasudil (FAS). Collagen crystal violet staining used assess morphological changes fibroblasts. Reverse transcription quantitative PCR western blotting analyze expression of key signaling molecules involved pathway. ALE, FAS, ROS groups was weak compared with group, while rate cell proliferation ROS, FAS slower that group. In addition, pathway, including transforming growth factor‑β1 (TGF‑β1), heat shock protein 47 (HSP47), collagen type I α1 (COL1A1), vascular endothelial factor 2 (VEGF2) fibroblast (FGF2), decreased model. Compared 3‑Hydroxy‑3‑Methylglutaryl‑CoA reductase (HMGCR) gene significantly lowered drug intervention groups, whereas farnesyl pyrophosphate synthase (FDPS) downregulated ALE but elevated groups. ras homolog family member A (RhoA) whilst kinase reduced Protein TGF‑β1, COL1A1 HSP47 following each three drugs Overall, rosuvastatin, aledronate inhibited synthesis. Rosuvastatin had strongest fibrosis other tested, suggesting this be a potential agent for clinical treatment cardiovascular disease.

Language: Английский

SAMSON and the Nocebo Effect: Management of Statin Intolerance DOI

Amrita Krishnamurthy,

Corey Bradley,

Rebecca R. Ascunce

et al.

Current Cardiology Reports, Journal Year: 2022, Volume and Issue: 24(9), P. 1101 - 1108

Published: June 27, 2022

Language: Английский

Citations

16
Antihyperlipidemic effect of Vaccinium dunalianum buds based on biological activity screening and LC-MS DOI

Jin-Han Yang,

Tong-Chen Bai,

Lu-Li Shi

et al.

Journal of Ethnopharmacology, Journal Year: 2023, Volume and Issue: 306, P. 116190 - 116190

Published: Jan. 21, 2023

Language: Английский

Citations

8
Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia DOI Creative Commons

Willemijn E. Corpeleijn,

Wouter J. de Waal,

Henk S. Schipper

et al.

Diabetologia, Journal Year: 2023, Volume and Issue: 67(1), P. 19 - 26

Published: Nov. 30, 2023

Abstract In the last few decades, atherosclerotic cardiovascular disease (ASCVD) risk has decreased dramatically among individuals affected by familial hypercholesterolaemia (FH) as a result of early initiation statin treatment in childhood. Contemporaneously important improvements care for people with diabetes have also been made, such prevention mortality from acute diabetic complications. However, type 1 still two to eight times higher death than general population. 20 years, landmark studies on excess diabetes, particular young adults, published. Although these were carried out different populations, all reached same conclusion: pronounced increased ASCVD. this review, we address role lipid abnormalities development ASCVD and FH. FH are diseases, lessons could be learned statins children FH, which may provide rationale more stringent control dyslipidaemia diabetes. Graphical

Language: Английский

Citations

8
Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease DOI
James Reston,

Andrew Buelt,

Mark Donahue

et al.

Annals of Internal Medicine, Journal Year: 2020, Volume and Issue: 173(10), P. 806 - 812

Published: Sept. 21, 2020

Strategies to improve patients' tolerance of and adherence statins may enhance the effectiveness dyslipidemia treatment in those at risk for cardiovascular disease (CVD).To assess benefits harms interventions statin patients CVD.MEDLINE, EMBASE, PubMed, Cochrane Library from December 2013 through May 2019 (English language only).Systematic reviews (SRs), randomized controlled trials (RCTs), cohort studies that addressed improving adherence.One investigator abstracted data assessed study quality, a second checked abstractions assessments accuracy.One SR, 1 RCT, 4 were included. The SR found intensified patient care improved decreased levels total serum cholesterol low-density lipoprotein (LDL-C) 6 months or more follow-up. Compared with discontinuation, nondaily dosing lowered LDL-C levels. One large suggested than 90% who discontinued could be rechallenged same different adherent year after statin-related adverse event led discontinuation. Two small reported previously intolerant had low baseline vitamin D able adhere supplementation.This is qualitative synthesis new evidence existing meta-analyses, several methodological shortcomings.Although strength most was very low, rechallenge (or lower dose) seem favorable options adherence.U.S. Department Veterans Affairs.

Language: Английский

Citations

23
Inhibition of the mevalonate pathway improves myocardial fibrosis DOI Open Access

Huifeng Xu,

Yi Shen, Chenyu Liang

et al.

Experimental and Therapeutic Medicine, Journal Year: 2021, Volume and Issue: 21(3)

Published: Jan. 18, 2021

The mevalonate (MVA) pathway serves an important role in ventricular remodeling. Targeting the MVA has protective effects against myocardial fibrosis. present study aimed to investigate mechanism behind these effects. Primary cultured cardiac fibroblasts from C57BL/6 mice were treated in vitro 5 groups: i) negative control; ii) angiotensin II (Ang II) model (1x10‑5 mol/l); iii) Ang + rosuvastatin (ROS); iv) alendronate (ALE); and v) fasudil (FAS). Collagen crystal violet staining used assess morphological changes fibroblasts. Reverse transcription quantitative PCR western blotting analyze expression of key signaling molecules involved pathway. ALE, FAS, ROS groups was weak compared with group, while rate cell proliferation ROS, FAS slower that group. In addition, pathway, including transforming growth factor‑β1 (TGF‑β1), heat shock protein 47 (HSP47), collagen type I α1 (COL1A1), vascular endothelial factor 2 (VEGF2) fibroblast (FGF2), decreased model. Compared 3‑Hydroxy‑3‑Methylglutaryl‑CoA reductase (HMGCR) gene significantly lowered drug intervention groups, whereas farnesyl pyrophosphate synthase (FDPS) downregulated ALE but elevated groups. ras homolog family member A (RhoA) whilst kinase reduced Protein TGF‑β1, COL1A1 HSP47 following each three drugs Overall, rosuvastatin, aledronate inhibited synthesis. Rosuvastatin had strongest fibrosis other tested, suggesting this be a potential agent for clinical treatment cardiovascular disease.

Language: Английский

Citations

18